Morgan Stanley Stays Neutral on Doximity, Highlights Strength in Video Module Business

Doximity, Inc. (NYSE:DOCS) is one of the best digital health stocks to buy now.

On November 3, 2025, Morgan Stanley maintained its Equal-Weight rating on Doximity and held its price target steady at $62. The firm’s analyst Craig Hettenbach cited third-quarter checks indicating stronger-than-expected growth, driven in large part by the company’s video module business. The note suggested that adoption momentum in this segment may be outperforming earlier expectations.

In addition, the analyst addressed concerns around potential competitive pressure from OpenEvidence, stating that it has seen no overlap or measurable impact on Doximity’s business from that company so far. While the rating remained neutral, the commentary pointed to a stable outlook supported by product-driven growth within key channels.

Numbers came later that week, on November 6, when Doximity reported Q2 FY26 revenue of $168.5 million, up 23% year over year, and adjusted EBITDA of $100.8 million (≈60% margin). Management guided Q3 FY26 revenue to $180–$181 million (~7% YoY) and FY26 revenue to $640–$646 million (~13% YoY).

Doximity, Inc. (NYSE:DOCS) is a digital platform built for medical professionals, offering tools for networking, telehealth, and physician marketing. The company provides a HIPAA-compliant communication suite and works with pharmaceutical and hospital systems to deliver targeted outreach to clinicians across the United States.

While we acknowledge the potential of DOCS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None.